Trials / Terminated
TerminatedNCT05592275
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3540378 in Adults With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 332 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3540378 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2023-02-03
- Primary completion
- 2025-01-22
- Completion
- 2025-01-22
- First posted
- 2022-10-24
- Last updated
- 2026-02-05
- Results posted
- 2026-02-05
Locations
137 sites across 12 countries: United States, Argentina, Brazil, Canada, Czechia, Hungary, Israel, Japan, Poland, Spain, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05592275. Inclusion in this directory is not an endorsement.